首页> 美国卫生研究院文献>The Journal of Biological Chemistry >miR-326-Histone Deacetylase-3 Feedback Loop Regulates the Invasion and Tumorigenic and Angiogenic Response to Anti-cancer Drugs
【2h】

miR-326-Histone Deacetylase-3 Feedback Loop Regulates the Invasion and Tumorigenic and Angiogenic Response to Anti-cancer Drugs

机译:miR-326-组蛋白脱乙酰基酶3反馈回路调节对抗癌药物的侵袭致瘤和血管生成反应

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Histone modification is known to be associated with multidrug resistance phenotypes. Cancer cell lines that are resistant or have been made resistant to anti-cancer drugs showed lower expression levels of histone deacetylase-3 (HDAC3), among the histone deacetylase(s), than cancer cell lines that were sensitive to anti-cancer drugs. Celastrol and Taxol decreased the expression of HDAC3 in cancer cell lines sensitive to anti-cancer drugs. HDAC3 negatively regulated the invasion, migration, and anchorage-independent growth of cancer cells. HDAC3 conferred sensitivity to anti-cancer drugs in vitro and in vivo. TargetScan analysis predicted miR-326 as a negative regulator of HDAC3. ChIP assays and luciferase assays showed a negative feedback loop between HDAC3 and miR-326. miR-326 decreased the apoptotic effect of anti-cancer drugs, and the miR-326 inhibitor increased the apoptotic effect of anti-cancer drugs. miR-326 enhanced the invasion and migration potential of cancer cells. The miR-326 inhibitor negatively regulated the tumorigenic, metastatic, and angiogenic potential of anti-cancer drug-resistant cancer cells. HDAC3 showed a positive feedback loop with miRNAs such as miR-200b, miR-217, and miR-335. miR-200b, miR-217, and miR-335 negatively regulated the expression of miR-326 and the invasion and migration potential of cancer cells while enhancing the apoptotic effect of anti-cancer drugs. TargetScan analysis predicted miR-200b and miR-217 as negative regulators of cancer-associated gene, a cancer/testis antigen, which is known to regulate the response to anti-cancer drugs. HDAC3 and miR-326 acted upstream of the cancer-associated gene. Thus, we show that the miR-326-HDAC3 feedback loop can be employed as a target for the development of anti-cancer therapeutics.
机译:已知组蛋白修饰与多药耐药性表型有关。在组蛋白脱乙酰基酶中,对抗癌药物具有抗性或已使其具有抗性的癌细胞系显示出比对抗癌药物敏感的癌细胞系低的组蛋白脱乙酰基酶-3(HDAC3)表达水平。 Celastrol和Taxol降低了HDAC3在对抗癌药物敏感的癌细胞系中的表达。 HDAC3负调控癌细胞的侵袭,迁移和锚定非依赖性生长。 HDAC3赋予了体内和体外对抗癌药物的敏感性。 TargetScan分析预测miR-326作为HDAC3的负调节剂。 ChIP分析和荧光素酶分析显示HDAC3和miR-326之间存在负反馈回路。 miR-326降低了抗癌药物的凋亡作用,而miR-326抑制剂则提高了抗癌药物的凋亡作用。 miR-326增强了癌细胞的侵袭和迁移潜能。 miR-326抑制剂负调节抗癌药物耐药癌细胞的致瘤,转移和血管生成潜能。 HDAC3对miRNA(例如miR-200b,miR-217和miR-335)显示出正反馈环。 miR-200b,miR-217和miR-335负调节miR-326的表达以及癌细胞的侵袭和迁移潜能,同时增强抗癌药物的凋亡作用。 TargetScan分析预测miR-200b和miR-217是癌症相关基因(癌症/睾丸抗原)的负调节剂,已知该基因可调节对抗癌药物的反应。 HDAC3和miR-326在癌症相关基因的上游起作用。因此,我们表明,miR-326-HDAC3反馈环可以用作抗癌疗法发展的目标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号